# CAC Score & CCTA - Quick Reference Guide

## CAC Score Interpretation (Agatston)

| Score Range | Risk Level | Annual Event Rate | Action |
|-------------|------------|-------------------|--------|
| 0 AU | Very Low | 0.11% | No statin, recheck 5-15 years |
| 1-10 AU | Low | ~0.3% | Consider statin if age >55 |
| 11-100 AU | Moderate | 0.7% | Statin recommended |
| 101-400 AU | Moderate-High | 1.4% | Statin + ezetimibe |
| 401-1000 AU | High | 2.1% | Intensive therapy |
| >1000 AU | Very High | 3-4% | Maximal therapy + cardiology |

## CAC Score = 0 Warranty Period

| Age | Gender | Diabetes | Lp(a) >50 | Repeat CAC in: |
|-----|--------|----------|-----------|----------------|
| <45 | M | No | No | 10-15 years |
| <45 | M | No | Yes | 5-7 years |
| <45 | M | Yes | Any | 3-5 years |
| 45-55 | M | No | No | 7-10 years |
| 45-55 | M | Yes | Any | 3-5 years |
| >55 | M | Yes | Any | 3 years |
| <55 | F | No | No | 10-15 years |
| >55 | F | Yes | Any | 3-5 years |

## CAD-RADS Classification (CCTA)

| CAD-RADS | Stenosis | 5-Year Event Rate | Management |
|----------|----------|-------------------|------------|
| 0 | 0% | 5% | Lifestyle only |
| 1 | 1-24% | 7% | Primary prevention |
| 2 | 25-49% | 11% | Secondary prevention |
| 3 | 50-69% | 15% | Stress test |
| 4A | 70-99% (1-2 vessels) | 23% | ICA likely |
| 4B | 70-99% (3 vessels or LM >50%) | 23% | ICA urgent |
| 5 | 100% (total occlusion) | 31% | ICA urgent |

## High-Risk Plaque Features (HRP)

| Feature | Definition | Significance |
|---------|------------|--------------|
| **Positive Remodeling** | Vessel area >10% larger than reference | Vulnerable plaque |
| **Low-Attenuation Plaque** | <30 HU | Lipid-rich, high risk |
| **Napkin-Ring Sign** | Hypodense core + hyperdense ring | Necrotic core, very high risk |
| **Spotty Calcification** | Calcification <3mm | Unstable plaque |

**HRP Score:**
- 0 features = Low risk
- 1 feature = Moderate risk
- 2 features = High risk
- 3+ features = Very high risk (HR 2.5 for MACE)

## Plaque Burden Score (P0-P4)

| Score | CAC Range | SIS (Segments) | Burden |
|-------|-----------|----------------|--------|
| P0 | 0 | 0 | None |
| P1 | 1-99 | 1-4 | Mild |
| P2 | 100-399 | 5-8 | Moderate |
| P3 | 400-999 | 9-12 | Moderate-Severe |
| P4 | ≥1000 | ≥13 | Extensive |

## Advanced Lipid Targets (Functional Medicine)

| Biomarker | Optimal | Target | High Risk |
|-----------|---------|--------|-----------|
| **ApoB** | <50 mg/dL | <65 mg/dL | >100 mg/dL |
| **Lp(a)** | <30 mg/dL | <50 mg/dL | >100 mg/dL |
| **LDL-P** | <1000 nmol/L | <1300 nmol/L | >2000 nmol/L |
| **hs-CRP** | <0.5 mg/L | <1 mg/L | >3 mg/L |
| **Lp-PLA2** | <150 ng/mL | <175 ng/mL | >235 ng/mL |

## Combined Risk Stratification (CAC + ApoB + Lp(a))

| CAC | ApoB | Lp(a) | 10-Year Risk | Strategy |
|-----|------|-------|--------------|----------|
| 0 | <80 | <50 | <5% | Lifestyle only |
| 0 | >80 | <50 | 5-10% | Consider statin |
| 0 | Any | >100 | 10-15% | Statin + anti-Lp(a) (future) |
| 1-99 | >80 | >50 | 15-20% | Statin + ezetimibe |
| 100-400 | >80 | >50 | 20-30% | Statin + ezetimibe + PCSK9i |
| >400 | Any | Any | >30% | Maximal therapy |

## CAC Progression Risk

| Annual Change | Risk Level | Action |
|--------------|------------|--------|
| <15% | Normal | Continue current therapy |
| 15-20% | Typical | Optimize lifestyle + meds |
| 20-30% | Accelerated | Intensive intervention |
| >30% | Very Accelerated | Cardiology referral |

## Functional Medicine Interventions

### Evidence-Based Supplements for CAC >400:
- **Vitamin K2 (MK-7):** 720 µg/day
- **Vitamin D3:** 25 µg/day (1000 IU)
- **Magnesium:** 400-600 mg/day
- **Omega-3 (EPA/DHA):** 2-4 g/day

### Lifestyle Interventions:
- **Diet:** Mediterranean or low-carb (reduces TG 25-30%)
- **Exercise:** 150 min/week moderate aerobic
- **Stress:** Meditation, yoga (reduces inflammation)
- **Sleep:** 7-9 hours (critical for recovery)

### Results from AVADEC Trial (2024):
- CAC progression reduced: Δ288 vs Δ380 (p=0.047)
- CV events reduced: 65% (1.9% vs 6.7%, p=0.048)

## Clinical Decision Algorithms

### Algorithm 1: Statin Decision
```
Intermediate Risk (PCE 7.5-20%) → Uncertain about statin?
   ↓
Order CAC Score
   ↓
CAC = 0        → Defer statin, reassess 5-10 years
CAC 1-99       → Shared decision (favor if age >55)
CAC 100-400    → Statin moderate/high intensity
CAC >400       → Statin high intensity + ezetimibe
```

### Algorithm 2: CCTA Follow-up
```
CAD-RADS 0-1   → Lifestyle, no follow-up imaging
CAD-RADS 2     → Secondary prevention, repeat 3-5 years
CAD-RADS 3     → Stress test or FFR-CT
CAD-RADS 4A    → ICA likely
CAD-RADS 4B/5  → ICA urgent
```

## Key Evidence (2024-2025)

### MESA Study (15+ years follow-up):
- CAC=0 in diabetes: Still low risk (<1%/year)
- CAC >400: Risk >20% (secondary prevention equivalent)
- Warranty period: 5-15 years (varies by demographics)

### CAD-RADS 2.0 (2022):
- Plaque burden score (P0-P4) added
- HRP features integrated
- FFR-CT functional assessment

### AVADEC Trial (2024):
- Vitamin K2 + D3 reduces CAC progression in CAC ≥400
- 65% reduction in CV events

### ACC 2025 Quantitative Plaque Statement:
- Positive remodeling + LAP = highest risk
- Napkin-ring sign: HR 2.5 for MACE
- Spotty calcification: Early instability marker

## When to Order Which Test?

### CAC Score (Non-contrast CT):
- **Best for:** Risk stratification, statin decision
- **Use when:** Intermediate risk (PCE 7.5-20%)
- **Cost:** $100-300
- **Radiation:** 1-3 mSv

### CCTA (Contrast CT):
- **Best for:** Symptomatic patients, rule-out CAD
- **Use when:** Stable chest pain, CAD-RADS needed
- **Cost:** $500-1500
- **Radiation:** 3-10 mSv

### Both Tests:
- **Best for:** Comprehensive assessment (CAC + anatomy)
- **Use when:** High risk, diabetes, strong family history

## Red Flags - Urgent Cardiology Referral

- CAC >1000
- CAD-RADS 4B or 5
- ≥3 HRP features
- CAC progression >30%/year
- Symptomatic with CAD-RADS ≥3

---

**Full Documentation:** See `/home/user/plenya/CAC-CCTA-STRATIFICATION.md`

**Implementation:** See Go models and API endpoints in main document

**Last Updated:** January 2026
